See more : Jubilee Gold Exploration Ltd. (JBULF) Income Statement Analysis – Financial Results
Complete financial analysis of Todos Medical Ltd. (TOMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Todos Medical Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Jupiter Mines Limited (JMXXF) Income Statement Analysis – Financial Results
- Hong Kong Johnson Holdings Co., Ltd. (1955.HK) Income Statement Analysis – Financial Results
- Chaoda Modern Agriculture (Holdings) Limited (CMGHF) Income Statement Analysis – Financial Results
- Country Garden Holdings Company Limited (CTRYF) Income Statement Analysis – Financial Results
- HouseFreedom Co.,Ltd. (8996.T) Income Statement Analysis – Financial Results
Todos Medical Ltd. (TOMDF)
About Todos Medical Ltd.
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70M | 12.23M | 5.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.39M | 7.85M | 3.82M | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.31M | 4.38M | 1.39M | -29.64K | -25.65K | -24.08K | -20.70K | -11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 56.01% | 35.84% | 26.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 620.00K | 824.00K | 9.86M | 755.70K | 459.18K | 720.53K | 317.91K | 374.02K | 336.47K | 377.31K | 312.17 |
| General & Administrative | 0.00 | 9.36M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Selling & Marketing | 0.00 | 3.48M | -3.06M | -667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.85M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Other Expenses | 0.00 | 0.00 | -53.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.06M | 13.67M | 15.65M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Cost & Expenses | 17.44M | 21.52M | 19.47M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Interest Income | 0.00 | 28.61K | 13.37K | 959.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Interest Expense | 14.85M | 28.61M | 3.83M | 958.74K | 75.43K | 12.44K | 78.78K | 0.00 | 0.00 | ||
| Depreciation & Amortization | 750.00K | 763.00K | 96.00K | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 434.00 | 275.00 | 0.28 |
| EBITDA | -9.39M | -9.72M | -14.17M | -7.78M | -1.35M | -1.31M | -708.19K | -819.08K | -400.41K | -339.26K | -244.22 |
| EBITDA Ratio | -122.08% | -59.33% | -465.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.75M | -9.29M | -14.26M | -3.52M | -1.38M | -1.34M | -728.89K | -830.98K | -400.85K | -339.53K | -244.49 |
| Operating Income Ratio | -126.68% | -75.93% | -273.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.23M | -34.03M | -15.51M | -8.30M | 921.34K | -1.34M | 75.43K | 12.44K | 78.78K | -42.29K | -11.63 |
| Income Before Tax | -24.98M | -43.31M | -29.77M | -11.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -381.82K | -256.12 |
| Income Before Tax Ratio | -324.64% | -354.16% | -571.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | 31.61M | 2.63M | -2.01M | 871.34K | -2.68M | 0.00 | 0.00 | 0.00 | -38.18K | -25.37 |
| Net Income | -24.99M | -74.92M | -32.40M | -9.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -343.64K | -230.75 |
| Net Income Ratio | -324.81% | -612.60% | -622.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
| Weighted Avg Shares Out (Dil) | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
Todos Medical to Present at The LD Micro Conference
Todos Medical academic partner fully enrolls second cohort of LymPro Alzheimer's Blood Test trial
Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days
Todos Medical updates investors on its lab Provista Diagnostics, its 3CL Pharma subsidiary, and its plans to uplist onto a major stock exchange
Todos Medical says unit will present final data from Tollovir Phase 2 clinical trial in hospitalized coronavirus patients at PMWC
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
Todos Medical reports dietary supplement 'excellent rescue agent' for Long COVID patient in case study following Paxlovid treatment
Todos Medical receives certificate of free sale for Tollovid Maximum Strength supplement
Todos Medical says set for study to assess potential product development of Tollovid to treat COVID-19 and Long COVID-19
Todos Medical to Present at the Emerging Growth Conference
Source: https://incomestatements.info
Category: Stock Reports